MNK News and Press, Mallinckrodt plc From 06/23/22

Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress PR Newswire -Post-hoc analyses showcase Mallinckrodt's commitment to patie...

Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context PR Newswire – Electronic medical chart analysis showed Acthar ...

Silence Therapeutics plc (NASDAQ:SLN) will receive a $3M research milestone payment from Mallinckrodt (OTCPK:MNKKQ) as the companies announced filing of a clinical trial application (CTA) for SLN501 targeting complement-mediated diseases. In July 2019, Silence and Mallinckrodt began...

A U.S. Bankruptcy Court in Delaware granted Mallinckrodt PLC (NYSE:MNK) (OTCPK:MNKKQ) to settle its opioid-related liabilities for nearly $1.7B, The Wall Street Journal reported. After a months-long trial, Judge John Dorsey of the U.S. Bankruptcy Court in Wilmington, Delaware, ...

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing. For further details see: Endo International: Hires Restructuring...

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likel...

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial...

Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) -- First approved donor site-free alternative to autograft for deep partial-thickness burns designed to handle like an autograft and...

Proprietary cylinder-free LungFit system that can produce NO from ambient air, leading to substantial benefits over traditional systems. Close to FDA approval for first product LungFit PH which will likely dominate a TAM of close to $500mil with few competitors. Razor-blade model ...

Members of the Sackler family who own Purdue Pharma raised their settlement offer in ongoing opioid litigation to $4.3b from $3b, according to a Reuters report.Sackler family members are offering to contribute $4.3b to help settle thousands of lawsuits from U.S. communities that are trying to...